These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic. Lyketsos CG; Corazzini K; Steele CD; Kraus MF J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704 [TBL] [Abstract][Full Text] [Related]
44. Alzheimer's disease: the role of tacrine therapy. Jogerst G Iowa Med; 1995 Oct; 85(10):409-11. PubMed ID: 7591656 [No Abstract] [Full Text] [Related]
45. Maximizing function in Alzheimer's disease: what role for tacrine? Smucker WD Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842 [TBL] [Abstract][Full Text] [Related]
46. Tacrine for senile dementia of Alzheimer's or Lewy body type. Wilcock GK; Scott MI Lancet; 1994 Aug; 344(8921):544. PubMed ID: 7914636 [No Abstract] [Full Text] [Related]
47. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of Tacrine and the measurement of outcomes of Alzheimer's disease. Int J Technol Assess Health Care; 1998; 14(2):398-9. PubMed ID: 9678977 [No Abstract] [Full Text] [Related]
49. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy. Boller F; Orgogozo JM Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536 [No Abstract] [Full Text] [Related]
50. [Tacrine in Alzheimer's disease]. López de Munain A Rev Neurol; 1997 Jul; 25 Suppl 1():S70-2. PubMed ID: 9280671 [No Abstract] [Full Text] [Related]
51. Alzheimer's disease: how to give and monitor tacrine therapy. Woo JK; Lantz MS Geriatrics; 1995 May; 50(5):50-3. PubMed ID: 7737527 [TBL] [Abstract][Full Text] [Related]
52. Tacrine in Alzheimer's disease. Davies B; Andrewes D; Stargatt R; Ames D; Tuckwell V; Davis S Lancet; 1989 Jul; 2(8655):163-4. PubMed ID: 2567933 [No Abstract] [Full Text] [Related]
53. [Clinical study of patients with Alzheimer's disease under treatment with tacrine]. García-López MT; Guardado-Santervás P Rev Neurol; 2001 Feb 16-28; 32(4):394-7. PubMed ID: 11398762 [No Abstract] [Full Text] [Related]
54. Alzheimer's disease: a new hope. Hasan MK; Mooney D W V Med J; 1994 Oct; 90(10):418-9. PubMed ID: 7801627 [TBL] [Abstract][Full Text] [Related]
55. Tacrine treatment in Alzheimer's disease enhances cerebral blood flow and mental status and decreases caregiver suffering. Harkins SW; Taylor JR; Mattay V; Regelson W Ann N Y Acad Sci; 1997 Sep; 826():472-4. PubMed ID: 9329726 [No Abstract] [Full Text] [Related]
56. Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia. Trzepacz PT; Ho V; Mallavarapu H Psychosomatics; 1996; 37(3):299-301. PubMed ID: 8849507 [No Abstract] [Full Text] [Related]
57. Tacrine as a treatment for Alzheimer's dementia: editor's note. An interim report from the FDA. A response from Summers et al. N Engl J Med; 1991 Jan; 324(5):349-52. PubMed ID: 1986300 [No Abstract] [Full Text] [Related]
58. Tacrine in the treatment of Alzheimer's disease. A clinical update and recent pharmacologic studies. Summers WK; Tachiki KH; Kling A Eur Neurol; 1989; 29 Suppl 3():28-32. PubMed ID: 2693104 [TBL] [Abstract][Full Text] [Related]
59. [Drugs for Alzheimer's disease]. Taurand P Soins; 1995 Mar; (594):61-2. PubMed ID: 7716573 [No Abstract] [Full Text] [Related]
60. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. Chatellier G; Lacomblez L BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]